Revenue ($USD) : $2,802,249,000
R&D spend : $256,889,000.00
Employees : 8,200
Fiscal year end : 12/31/22
CEO : Norman Schwartz
Bio-Rad will be an interesting company to watch as the demand for the COVID-19-related diagnostics that boosted business over the past few years continues to fall. The company this year initiated a $500 million share repurchase program. –SW